Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedJul 18, 2026
DataAggregated Company Financials
Companies17
  • 7D-1.4%
  • 3M-13.2%
  • 1Y22.9%
  • YTD-3.8%

Over the last 7 days, the Pharma industry has dropped 1.4%, driven by a pullback from AstraZeneca of 1.9%. Over the past 12 months, the industry was up 23%. Earnings are forecast to grow by 10% annually.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 18 Jul 2026UK£310.2bUK£91.8bUK£15.8b19.7x19.6x3.4x
Mon, 15 Jun 2026UK£323.3bUK£92.0bUK£15.8b17.9x20.4x3.5x
Wed, 13 May 2026UK£324.2bUK£91.6bUK£15.7b17.8x20.6x3.5x
Fri, 10 Apr 2026UK£361.7bUK£90.5bUK£15.6b19.5x23.2x4x
Sun, 08 Mar 2026UK£345.0bUK£90.6bUK£15.6b20.5x22.1x3.8x
Tue, 03 Feb 2026UK£334.7bUK£88.7bUK£14.5b23.7x23.1x3.8x
Thu, 01 Jan 2026UK£326.0bUK£89.4bUK£14.6b21.9x22.3x3.6x
Sat, 29 Nov 2025UK£327.4bUK£90.2bUK£14.7b21.7x22.2x3.6x
Mon, 27 Oct 2025UK£296.9bUK£88.1bUK£11.8b20.5x25.2x3.4x
Wed, 24 Sep 2025UK£270.2bUK£87.4bUK£11.7b18.5x23.1x3.1x
Fri, 22 Aug 2025UK£286.2bUK£87.8bUK£11.7b21.8x24.4x3.3x
Sun, 20 Jul 2025UK£253.3bUK£86.7bUK£10.7b26.7x23.8x2.9x
Tue, 17 Jun 2025UK£270.2bUK£86.2bUK£10.6b26.8x25.5x3.1x
Thu, 15 May 2025UK£252.5bUK£87.2bUK£10.7b25.6x23.5x2.9x
Sat, 12 Apr 2025UK£248.1bUK£87.2bUK£9.7b28.8x25.7x2.8x
Mon, 10 Mar 2025UK£293.8bUK£87.7bUK£9.6b29.2x30.6x3.3x
Wed, 05 Feb 2025UK£273.8bUK£86.9bUK£9.0b30.4x30.4x3.2x
Fri, 03 Jan 2025UK£227.9bUK£76.0bUK£7.9b31.4x29x3x
Sun, 01 Dec 2024UK£226.5bUK£74.7bUK£7.7b32x29.4x3x
Tue, 29 Oct 2024UK£247.4bUK£72.5bUK£9.1b28.7x27.3x3.4x
Thu, 26 Sep 2024UK£248.9bUK£71.5bUK£8.9b31.1x27.8x3.5x
Sat, 24 Aug 2024UK£275.7bUK£71.8bUK£8.9b41.6x30.8x3.8x
Mon, 22 Jul 2024UK£257.4bUK£70.9bUK£9.5b35.2x27.2x3.6x
Wed, 19 Jun 2024UK£266.1bUK£71.5bUK£9.6b31x27.8x3.7x
Fri, 17 May 2024UK£269.5bUK£71.7bUK£9.6b36.2x28.1x3.8x
Sun, 14 Apr 2024UK£248.1bUK£71.4bUK£9.8b33.2x25.4x3.5x
Tue, 12 Mar 2024UK£239.3bUK£70.2bUK£9.7b31.7x24.7x3.4x
Thu, 08 Feb 2024UK£237.4bUK£69.1bUK£9.6b35.8x24.8x3.4x
Sat, 06 Jan 2024UK£241.2bUK£68.8bUK£10.7b36x22.6x3.5x
Mon, 04 Dec 2023UK£228.1bUK£68.9bUK£10.7b34.1x21.4x3.3x
Wed, 01 Nov 2023UK£232.2bUK£70.7bUK£10.4b53.1x22.4x3.3x
Fri, 29 Sep 2023UK£245.8bUK£70.5bUK£10.4b75.9x23.7x3.5x
Sun, 27 Aug 2023UK£235.2bUK£69.4bUK£10.2b53.5x23x3.4x
Tue, 25 Jul 2023UK£237.8bUK£67.4bUK£7.8b52x30.3x3.5x
Price to Earnings Ratio

30.3x


Total Market Cap: UK£237.8bTotal Earnings: UK£7.8bTotal Revenue: UK£67.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 25x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 19.6x which is lower than its 3-year average PE of 25.0x.
  • The industry is trading close to its 3-year average PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 26% per year over the last three years.
  • Revenues for these companies have grown 11% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market1.03%
Healthcare-1.25%
Pharma-1.42%
Pharma-1.42%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
HLN HaleonUK£3.733.2%
+UK£1.0b		4.1%PE19.7x
HCM HUTCHMED (China)UK£1.756.1%
+UK£86.0m		-32.2%PE4.4x
IMM ImmuPharmaUK£0.04511.2%
+UK£2.8m		97.4%PB40.9x
SAR Sareum HoldingsUK£0.244.3%
+UK£1.4m		33.3%PB27.9x
AGY Allergy TherapeuticsUK£0.0670.3%
+UK£1.3m		-18.8%PS7.4x

Latest News

GSK
UK£19.17
GSK
7D
-2.3%
1Y
42.2%
AZN
UK£125.94
AstraZeneca
7D
-1.9%
1Y
22.3%
Narrative Update • Jul 16

AZN: Trial Setbacks And Oncology Deals Will Shape Medium Term Credibility

AstraZeneca's updated analyst price targets show a modest reset lower, with recent research pointing to greater uncertainty around medium term revenue catalysts and mixed trial outcomes, even as some analysts continue to highlight areas of support within the broader pipeline and existing portfolio. Analyst Commentary Recent research on AstraZeneca highlights a mix of caution and support, with several firms revisiting their models after the CARDIO TTRansform outcome and reassessing how much risk investors are taking on around the medium term growth story.
EAH
UK£0.88
ECO Animal Health Group
7D
-0.6%
1Y
8.7%
Narrative Update • Jul 15

EAH: Poultry Vaccine Rollout Will Support Higher Sustainable Profitability

Analysts have adjusted their fair value estimate for ECO Animal Health Group from £1.75 to £2.02. This reflects updated assumptions on discount rate, revenue growth, profit margin and future P/E multiples.
POLB
UK£0.061
Poolbeg Pharma
7D
-12.1%
1Y
99.7%
HIK
UK£15.61
Hikma Pharmaceuticals
7D
-1.5%
1Y
-22.3%
Narrative Update • Jul 14

HIK: US Manufacturing Expansion Will Support Future Earnings Rebound

Analysts have trimmed their price target on Hikma Pharmaceuticals to £24.79 from £26.36, reflecting updated assumptions for slightly higher discount rates, more moderate revenue expectations, and a marginally softer profit margin and future P/E outlook. What’s in the News for Hikma Pharmaceuticals Hikma plans to invest $267 million to expand manufacturing operations in Columbus and Bedford, Ohio, with a target of creating 350 new jobs across injectable, oral solid dose, and nasal inhalation facilities.
STX
UK£0.062
Shield Therapeutics
7D
-3.1%
1Y
74.6%
Narrative Update • Jul 07

STX: Japan Trial Progress Will Drive Future Earnings Upside

Analysts have reduced their fair value estimate for Shield Therapeutics from £0.14 to £0.12, reflecting updated assumptions around revenue growth, profit margins, and a higher expected future P/E multiple. What’s in the News for Shield Therapeutics Shield Therapeutics reported that partner MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc., enrolled the first patient in a Phase II clinical trial in Japan for ACCRUFeR (ferric maltol) as a potential treatment for Pulmonary Arterial Hypertension, following confirmation of the development plan by Japan’s Pharmaceuticals and Medical Devices Agency, source: company announcement.
HCM
UK£1.75
HUTCHMED (China)
7D
6.1%
1Y
-32.2%
HLN
UK£3.73
Haleon
7D
3.2%
1Y
4.1%
Narrative Update • Jul 01

HLN: Lower Forward P E Assumptions Will Pressure Future Share Price

Haleon’s analyst price target has been trimmed by £0.10 to £3.15, as analysts factor in a slightly lower assumed future P/E, alongside recent Street moves that have reduced targets and, in one case, shifted the stock to a Neutral stance. Analyst Commentary Recent Street research on Haleon points to a more cautious tone, with several bearish analysts trimming price targets and reassessing risk around valuation, execution and future growth assumptions.
FUM
UK£0.0031
Futura Medical
7D
-16.2%
1Y
-97.2%
INC
UK£0.013
Incanthera
7D
-22.9%
1Y
-73.0%
SAR
UK£0.24
Sareum Holdings
7D
4.3%
1Y
33.3%
IMM
UK£0.045
ImmuPharma
7D
11.2%
1Y
97.4%
AGY
UK£0.067
Allergy Therapeutics
7D
0.3%
1Y
-18.8%
NFX
UK£0.0017
Nuformix
7D
3.0%
1Y
88.9%